Detec­tion of anti­bod­ies against SARS-CoV‑2

By

Detec­tion of anti­bod­ies against SARS-CoV‑2

Devel­op­ment of an auto­mated flow-based chemi­lu­min­es­cence microar­ray immun­oas­say (CL-MIA) for the detec­tion of anti­bod­ies against SARS-CoV‑2 RBD/spike pro­tein and N pro­tein in human serum and plasma in less than 8 min with high spe­cificity and sensitivity.

In the face of the COVID-19 pan­demic, the need for rapid ser­o­lo­gical tests that allow mul­ti­plex­ing emerged, as anti­body sero­pos­it­iv­ity can instruct about indi­vidual immunity after an infec­tion with SARS-CoV‑2 or after vac­cin­a­tion. As many com­mer­cially avail­able anti­body tests are either time-con­sum­ing or tend to pro­duce false neg­at­ive or false pos­it­ive res­ults when only one anti­gen is con­sidered, we developed an auto­mated, flow-based chemi­lu­min­es­cence microar­ray immun­oas­say (CL-MIA) that allows for the detec­tion of anti­bod­ies to SARS-CoV‑2 RBD/spike pro­tein and N pro­tein in human serum and plasma in less than 8 min. The CoV­Rapid CL-MIA was tested with SARS-CoV‑2 ser­o­logy pos­it­ive or neg­at­ive samples, res­ult­ing in 100% dia­gnostic spe­cificity and 100% dia­gnostic sens­it­iv­ity, thus out­com­pet­ing other com­mer­cial tests run on the same sample set.

Auto­mated, flow-based chemi­lu­min­es­cence microar­ray immun­oas­say for the rapid mul­ti­plex detec­tion of IgG anti­bod­ies to SARS-CoV‑2 in human serum and plasma (CoV­Rapid CL-MIA)

Julia Klüp­fel & Rosa Car­o­lina Koros & Ker­stin Dehne & Martin Ungerer & Silvia Würstle & Josef Maut­ner & Martin Feuer­herd & Ulrike Protzer & Oliver Hay­den & Martin Els­ner & Michael Seidel

PDF